Quantitative bibliometric insights into cisplatin resistance in breast cancer (2010–2024): Implications for drug development

This study presents an extensive bibliometric analysis of cisplatin resistance (CR) in breast cancer (BC) from 2010 to 2024, elucidating global research trends, collaboration networks, and prospective research directions. Particular attention is given to novel therapeutic strategies, such as multi-target drug design and biomarker-guided treatments, aimed at overcoming challenges associated with drug resistance. This study utilizes the PubMed database and employs a topic search strategy, integrating the R package “bibliometrix” to conduct an in-depth analysis of the number of published documents, patterns of collaboration, journal impact, author contributions, institutional outputs, national collaboration networks, as well as keyword co-occurrences and citation networks. China and the United States are the principal contributors to research in this domain, with the Islamic Azad University and the journal Cancers serving as the primary platforms for academic dissemination. Notable researchers in this field include Wang, B. and Chekhun, V. F. Furthermore, the study highlights three particularly significant publications. Research hotspots include CR, triple-negative BC, BRCA1, DNA repair, microRNA, prostate cancer, ceRNA, LINCRNA, and prognosis, while trending topics comprise CR, triple-negative BC, BRCA1, autophagy, cytotoxicity, and DNA damage. This study provides actionable insights into research trends and translational opportunities in BC CR, emphasizing the integration of microRNA regulation, autophagy mechanisms, and multi-target drug design in clinical applications. Collaborative efforts between leading countries and institutions are pivotal to advancing therapeutic strategies and improving patient outcomes.